Skip to main content
Erschienen in: Journal of Gastroenterology 2/2018

24.07.2017 | Original Article—Liver, Pancreas, and Biliary Tract

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease

verfasst von: Takashi Nakahara, Hideyuki Hyogo, Atsushi Ono, Yuko Nagaoki, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Nobuhiko Hiraga, Clair Nelson Hayes, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Hiromi Abe-Chayama, Hisako Furusho, Tomoaki Shintani, Hidemi Kurihara, Mutsumi Miyauchi, Takashi Takata, Koji Arihiro, Kazuaki Chayama

Erschienen in: Journal of Gastroenterology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

The risk factors in the progression of nonalcoholic fatty liver disease (NAFLD) have not been fully clarified. Porphyromonas gingivalis (P.g) has been considered to be a confounding risk factor for systemic diseases. We aimed to evaluate the effect of P.g infection on risk of progression to NASH.

Methods

(1) Serum IgG antibody titers against P.g fimbriae (fimA) in 200 biopsy-proven NAFLD patients were measured by ELISA and compared with histological findings. (2) C57BL/6J mice were fed a control diet (CD) or high-fat diet (HFD) with or without P.g-odontogenic infection and analyzed histologically. Mouse livers were analyzed using CE–TOFMS and LC–TOFMS.

Results

(1) A significant correlation between fibrosis progression and antibody titers against P.g possessing fimA type 4 was identified (P = 0.0081). Multivariate analysis identified older age and type 4 P.g-positivity as risk factors for advanced fibrosis. (2) Fibrosis and steatosis were more severe in HFD P.g(+) mice compared with HFD P.g(−) mice. In metabolome analysis, fatty acid metabolism was significantly disrupted with HFD in P.g-infected mouse livers. Monounsaturated/saturated fatty acid ratios were significantly higher in the HFD P.g(+) group than in the HFD P.g(−) group (P < 0.05). Moreover, expression levels of SCD1 and ELOVL6 were significantly reduced.

Conclusions

These results suggest that P.g infection is an important risk factor for pathological progression in NAFLD. Increase in the monounsaturated/saturated fatty acid ratio may be an important change that facilitates progression of NAFLD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMed Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMed
3.
Zurück zum Zitat Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMed
4.
Zurück zum Zitat Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–93.CrossRefPubMed Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–93.CrossRefPubMed
5.
Zurück zum Zitat Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.CrossRefPubMed
6.
Zurück zum Zitat Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–61.CrossRefPubMed Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–61.CrossRefPubMed
7.
Zurück zum Zitat Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477–84.CrossRefPubMed Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49:1477–84.CrossRefPubMed
8.
Zurück zum Zitat Hamada S, Fujiwara T, Morishima S, et al. Molecular and immunological characterization of the fimbriae of Porphyromonas gingivalis. Microbiol Immunol. 1994;38:921–30.CrossRefPubMed Hamada S, Fujiwara T, Morishima S, et al. Molecular and immunological characterization of the fimbriae of Porphyromonas gingivalis. Microbiol Immunol. 1994;38:921–30.CrossRefPubMed
9.
Zurück zum Zitat Hamada S, Takada H, Ogawa T, et al. Lipopolysaccharides of oral anaerobes associated with chronic inflammation: chemical and immunomodulating properties. Int Rev Immunol. 1990;6:247–61.CrossRefPubMed Hamada S, Takada H, Ogawa T, et al. Lipopolysaccharides of oral anaerobes associated with chronic inflammation: chemical and immunomodulating properties. Int Rev Immunol. 1990;6:247–61.CrossRefPubMed
10.
Zurück zum Zitat Wilson M. Biological activities of lipopolysaccharides from oral bacteria and their relevance to the pathogenesis of chronic periodontitis. Sci Prog. 1995;78(Pt 1):19–34.PubMed Wilson M. Biological activities of lipopolysaccharides from oral bacteria and their relevance to the pathogenesis of chronic periodontitis. Sci Prog. 1995;78(Pt 1):19–34.PubMed
11.
Zurück zum Zitat Seymour GJ, Ford PJ, Cullinan MP, et al. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect. 2007;13(Suppl 4):3–10.CrossRefPubMed Seymour GJ, Ford PJ, Cullinan MP, et al. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect. 2007;13(Suppl 4):3–10.CrossRefPubMed
12.
Zurück zum Zitat Pizzo G, Guiglia R, Lo Russo L, et al. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur J Intern Med. 2010;21:496–502.CrossRefPubMed Pizzo G, Guiglia R, Lo Russo L, et al. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur J Intern Med. 2010;21:496–502.CrossRefPubMed
13.
Zurück zum Zitat Wada K, Kamisaki Y. Roles of oral bacteria in cardiovascular diseases—from molecular mechanisms to clinical cases: involvement of Porphyromonas gingivalis in the development of human aortic aneurysm. J Pharmacol Sci. 2010;113:115–9.CrossRefPubMed Wada K, Kamisaki Y. Roles of oral bacteria in cardiovascular diseases—from molecular mechanisms to clinical cases: involvement of Porphyromonas gingivalis in the development of human aortic aneurysm. J Pharmacol Sci. 2010;113:115–9.CrossRefPubMed
14.
Zurück zum Zitat Figuero E, Sanchez-Beltran M, Cuesta-Frechoso S, et al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011;82:1469–77.CrossRefPubMed Figuero E, Sanchez-Beltran M, Cuesta-Frechoso S, et al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011;82:1469–77.CrossRefPubMed
15.
Zurück zum Zitat Iwamoto K, Kanno K, Hyogo H, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298–304.CrossRefPubMed Iwamoto K, Kanno K, Hyogo H, et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008;43:298–304.CrossRefPubMed
16.
Zurück zum Zitat Dickinson DP, Kubiniec MA, Yoshimura F, et al. Molecular cloning and sequencing of the gene encoding the fimbrial subunit protein of Bacteroides gingivalis. J Bacteriol. 1988;170:1658–65.CrossRefPubMedPubMedCentral Dickinson DP, Kubiniec MA, Yoshimura F, et al. Molecular cloning and sequencing of the gene encoding the fimbrial subunit protein of Bacteroides gingivalis. J Bacteriol. 1988;170:1658–65.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tabeta K, Tanabe N, Yonezawa D, et al. Elevated antibody titers to Porphyromonas gingivalis as a possible predictor of ischemic vascular disease—results from the Tokamachi–Nakasato cohort study. J Atheroscler Thromb. 2011;18:808–17.CrossRefPubMed Tabeta K, Tanabe N, Yonezawa D, et al. Elevated antibody titers to Porphyromonas gingivalis as a possible predictor of ischemic vascular disease—results from the Tokamachi–Nakasato cohort study. J Atheroscler Thromb. 2011;18:808–17.CrossRefPubMed
18.
Zurück zum Zitat Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:16.CrossRefPubMedPubMedCentral Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:16.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol. 2013;48:1259–70.CrossRefPubMed Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol. 2013;48:1259–70.CrossRefPubMed
20.
Zurück zum Zitat Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711–8.CrossRefPubMed Hyogo H, Tazuma S, Arihiro K, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57:1711–8.CrossRefPubMed
21.
Zurück zum Zitat Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27:108–13.CrossRefPubMed Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol. 1997;27:108–13.CrossRefPubMed
22.
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
23.
Zurück zum Zitat Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed
24.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
25.
Zurück zum Zitat Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300–6.CrossRefPubMed Yoneda M, Fujii H, Sumida Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300–6.CrossRefPubMed
26.
Zurück zum Zitat Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S11–6.PubMed Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S11–6.PubMed
27.
Zurück zum Zitat Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin N Am. 2007;91:1125–49.CrossRefPubMed Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin N Am. 2007;91:1125–49.CrossRefPubMed
28.
Zurück zum Zitat Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010;8:481–90.CrossRefPubMed Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010;8:481–90.CrossRefPubMed
29.
Zurück zum Zitat Nakano K, Inaba H, Nomura R, et al. Distribution of Porphyromonas gingivalis fimA genotypes in cardiovascular specimens from Japanese patients. Oral Microbiol Immunol. 2008;23:170–2.CrossRefPubMed Nakano K, Inaba H, Nomura R, et al. Distribution of Porphyromonas gingivalis fimA genotypes in cardiovascular specimens from Japanese patients. Oral Microbiol Immunol. 2008;23:170–2.CrossRefPubMed
30.
Zurück zum Zitat Amano A, Kuboniwa M, Nakagawa I, et al. Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000;79:1664–8.CrossRefPubMed Amano A, Kuboniwa M, Nakagawa I, et al. Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000;79:1664–8.CrossRefPubMed
31.
Zurück zum Zitat Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4:4828.CrossRefPubMedPubMedCentral Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 2014;4:4828.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20:9072–89.PubMedPubMedCentral Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20:9072–89.PubMedPubMedCentral
33.
Zurück zum Zitat Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.CrossRefPubMedPubMedCentral Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–5.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Basantani MK, Sitnick MT, Cai L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318–29.CrossRefPubMedPubMedCentral Basantani MK, Sitnick MT, Cai L, et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318–29.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Yamada K, Mizukoshi E, Sunagozaka H, et al. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 2015;35:582–90.CrossRefPubMed Yamada K, Mizukoshi E, Sunagozaka H, et al. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 2015;35:582–90.CrossRefPubMed
36.
Zurück zum Zitat Wang X, Cao Y, Fu Y, et al. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis. 2011;10:234.CrossRefPubMedPubMedCentral Wang X, Cao Y, Fu Y, et al. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis. 2011;10:234.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–90.CrossRefPubMed Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081–90.CrossRefPubMed
38.
Zurück zum Zitat Matsuzaka T, Atsumi A, Matsumori R, et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology. 2012;56:2199–208.CrossRefPubMed Matsuzaka T, Atsumi A, Matsumori R, et al. Elovl6 promotes nonalcoholic steatohepatitis. Hepatology. 2012;56:2199–208.CrossRefPubMed
39.
Zurück zum Zitat Wang X, Ren Q, Wu T, et al. Ezetimibe prevents the development of nonalcoholic fatty liver disease induced by highfat diet in C57BL/6J mice. Mol Med Rep. 2014;10:2917–23.CrossRefPubMedPubMedCentral Wang X, Ren Q, Wu T, et al. Ezetimibe prevents the development of nonalcoholic fatty liver disease induced by highfat diet in C57BL/6J mice. Mol Med Rep. 2014;10:2917–23.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Fernandez Gianotti T, Burgueno A, Gonzales Mansilla N, et al. Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization. PLoS One. 2013;8:e76912.CrossRefPubMedPubMedCentral Fernandez Gianotti T, Burgueno A, Gonzales Mansilla N, et al. Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization. PLoS One. 2013;8:e76912.CrossRefPubMedPubMedCentral
Metadaten
Titel
Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease
verfasst von
Takashi Nakahara
Hideyuki Hyogo
Atsushi Ono
Yuko Nagaoki
Tomokazu Kawaoka
Daiki Miki
Masataka Tsuge
Nobuhiko Hiraga
Clair Nelson Hayes
Akira Hiramatsu
Michio Imamura
Yoshiiku Kawakami
Hiroshi Aikata
Hidenori Ochi
Hiromi Abe-Chayama
Hisako Furusho
Tomoaki Shintani
Hidemi Kurihara
Mutsumi Miyauchi
Takashi Takata
Koji Arihiro
Kazuaki Chayama
Publikationsdatum
24.07.2017
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 2/2018
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1368-4

Weitere Artikel der Ausgabe 2/2018

Journal of Gastroenterology 2/2018 Zur Ausgabe

Original Article—Alimentary Tract

Celiac disease in non-clinical populations of Japan

Original Article—Liver, Pancreas, and Biliary Tract

Response criteria of tolvaptan for the treatment of hepatic edema

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.